Laboratory tests in primary care · by Dr Solange Déplanque and Dr Michaël Rochoy

Parkinson's disease

Neurology · Known disease · updated 2026-10-30

BioMG follows French guidelines. Adapt it to the guidelines and the tests available where you practise.

Frequency: 0.83% (827.5 per 100 000 inhabitants: mean of 4 French studies, with a sample of over-65s judged overestimated) [1]

Parkinson's disease

Detailed explanation and international comparison (in French): read it in English (machine translation)

Before and during an ergot-derived dopamine agonist (bromocriptine, lisuride)

Laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Parkinsonism in a young patient: Wilson's disease

Laboratory tests

Detailed explanation and international comparison (in French): read it in English (machine translation)

Sources (8)
  1. GUIDE DU PARCOURS DE SOINS Maladie de Parkinson
  2. Höglinger G, et al.; German Parkinson's Guidelines Committee. Diagnosis and treatment of Parkinson's disease (guideline of the German Society for Neurology). Neurol Res Pract. 2024;6(1):30 (version abrégée en anglais de la recommandation S2k de la DGN, AWMF 030/010, mise à jour du 30 novembre 2023).
  3. National Institute for Health and Care Excellence (NICE). Parkinson's disease in adults. Guideline NG71, 19 juillet 2017.
  4. Gazewood JD, Richards DR, Clebak K. Parkinson disease: an update. Am Fam Physician. 2013;87(4):267-273.
  5. Assurance maladie. Nomenclature des actes de biologie médicale (NABM), version 105 : actes 0547 (cuivre sérique), 1809 (céruléoplasmine), 2008 (cuivre urinaire) ; absence d'acte actif pour la vitesse de sédimentation.
  6. ANSM. Résumé des caractéristiques du produit PARLODEL 10 mg, gélule (bromocriptine), rubriques 4.1, 4.3 et 4.4 ; base de données publique des médicaments, page « extrait » consultée le 13/10/2026 (mise à jour du 29/09/2026).
  7. Medicines and Healthcare products Regulatory Agency (MHRA). Ergot-derived dopamine agonists: risk of fibrosis. Drug Safety Update, juillet 2008, vol. 1, n° 12, p. 9 (mis en ligne sur gov.uk le 11 décembre 2014).
  8. Alkhouri N, Gonzalez-Peralta RP, Medici V. Wilson disease: a summary of the updated AASLD Practice Guidance. Hepatol Commun. 2023;7(6):e0150.